225 related articles for article (PubMed ID: 23299001)
21. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.
Halperin SA; Gupta A; Jeanfreau R; Klein NP; Reisinger K; Walter E; Bedell L; Gill C; Dull PM
Vaccine; 2010 Nov; 28(50):7865-72. PubMed ID: 20943209
[TBL] [Abstract][Full Text] [Related]
22. Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review.
Ghanem S; Hassan S; Saad R; Dbaibo GS
Expert Opin Biol Ther; 2013 Aug; 13(8):1197-205. PubMed ID: 23815506
[TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America.
Stamboulian D; Lopardo G; Lopez P; Cortes-Barbosa C; Valencia A; Bedell L; Karsten A; Dull PM
Int J Infect Dis; 2010 Oct; 14(10):e868-75. PubMed ID: 20655261
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age.
Black S; Klein NP; Shah J; Bedell L; Karsten A; Dull PM
Vaccine; 2010 Jan; 28(3):657-63. PubMed ID: 19895922
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers.
Bona G; Castiglia P; Zoppi G; de Martino M; Tasciotti A; D'Agostino D; Han L; Smolenov I
Vaccine; 2016 Jun; 34(29):3363-70. PubMed ID: 27181507
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age.
Marshall GS; Pelton SI; Robertson CA; Oster P
Hum Vaccin Immunother; 2022 Nov; 18(6):2099142. PubMed ID: 35947774
[TBL] [Abstract][Full Text] [Related]
27. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.
Jacobson RM; Jackson LA; Reisinger K; Izu A; Odrljin T; Dull PM
Pediatr Infect Dis J; 2013 Apr; 32(4):e170-7. PubMed ID: 23114372
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of MenACWY-CRM in Korean Military Recruits: Influence of Tetanus-Diphtheria Toxoid Vaccination on the Vaccine Response to MenACWY-CRM.
Kim HW; Park IH; You S; Yu HT; Oh IS; Sung PS; Shin EC; Kim KH
Yonsei Med J; 2016 Nov; 57(6):1511-6. PubMed ID: 27593883
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years.
Lalwani S; Agarkhedkar S; Gogtay N; Palkar S; Agarkhedkar S; Thatte U; Vakil H; Jonnalagedda R; Pedotti P; Hoyle M; Bhusal C; Arora A
Int J Infect Dis; 2015 Sep; 38():36-42. PubMed ID: 26166699
[TBL] [Abstract][Full Text] [Related]
30. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine.
Keshavan P; Pellegrini M; Vadivelu-Pechai K; Nissen M
Expert Rev Vaccines; 2018 Oct; 17(10):865-880. PubMed ID: 30198805
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults.
Lee HJ; Chung MH; Kim WJ; Hong YJ; Choi KM; Lee J; Oh CE; Welsch JA; Kim KH; Hong KB; Dagnew AF; Bock H; Dull PM; Odrljin T
Int J Infect Dis; 2014 Nov; 28():204-10. PubMed ID: 25316331
[TBL] [Abstract][Full Text] [Related]
32. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.
Keyserling H; Papa T; Koranyi K; Ryall R; Bassily E; Bybel MJ; Sullivan K; Gilmet G; Reinhardt A
Arch Pediatr Adolesc Med; 2005 Oct; 159(10):907-13. PubMed ID: 16203934
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger EC; Meyer S; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(2):105-14. PubMed ID: 25483566
[TBL] [Abstract][Full Text] [Related]
34. A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.
Ruiz Garcia Y; Abitbol V; Pellegrini M; Bekkat-Berkani R; Soumahoro L
Infect Dis Ther; 2022 Apr; 11(2):639-655. PubMed ID: 34591258
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults.
Gasparini R; Conversano M; Bona G; Gabutti G; Anemona A; Dull PM; Ceddia F
Clin Vaccine Immunol; 2010 Apr; 17(4):537-44. PubMed ID: 20164251
[TBL] [Abstract][Full Text] [Related]
36. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.
Dull PM; McIntosh ED
Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895
[TBL] [Abstract][Full Text] [Related]
37. Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
Collins JP; Crowe SJ; Ortega-Sanchez IR; Bahta L; Campos-Outcalt D; Loehr J; Morgan RL; Poehling KA; McNamara LA
MMWR Morb Mortal Wkly Rep; 2024 Apr; 73(15):345-350. PubMed ID: 38635488
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
[TBL] [Abstract][Full Text] [Related]
39. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration.
Gasparini R; Tregnaghi M; Keshavan P; Ypma E; Han L; Smolenov I
Pediatr Infect Dis J; 2016 Jan; 35(1):81-93. PubMed ID: 26398743
[TBL] [Abstract][Full Text] [Related]
40. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents.
Baxter R; Reisinger K; Block SL; Percell S; Odrljin T; Dull PM; Smolenov I
Pediatr Infect Dis J; 2014 Nov; 33(11):1169-76. PubMed ID: 24911896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]